Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.

Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators.

N Engl J Med. 2017 Mar 30;376(13):1211-1222. doi: 10.1056/NEJMoa1700518. Epub 2017 Mar 18.

2.

Relationship Between Abnormalities on High-Resolution Computerized Tomography, Pulmonary Function, and Bronchoalveolar Lavage in Progressive Systemic Sclerosis.

Cakmak G, Selcuk Can T, Gundogdu S, Akman C, Ikitimur H, Musellim B, Ongen G.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Dec 23;33(4):349-354.

PMID:
28079847
3.

Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.

Ozguler Y, Hatemi G, Ugurlu S, Seyahi E, Melikoglu M, Borekci S, Atahan E, Ongen G, Hamuryudan V.

Rheumatol Int. 2016 Dec;36(12):1719-1725. Epub 2016 Oct 3.

PMID:
27699578
4.

Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.

Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM; APEX Investigators.

N Engl J Med. 2016 Aug 11;375(6):534-44. doi: 10.1056/NEJMoa1601747. Epub 2016 May 27.

5.

The role of an activity monitor in the objective evaluation of patients with pulmonary hypertension.

Okumus G, Aslan GK, Arseven O, Ongen G, Issever H, Kıyan E.

Clin Respir J. 2016 May 5. doi: 10.1111/crj.12495. [Epub ahead of print]

PMID:
27149246
6.

Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-α treatment.

Borekci S, Atahan E, Demir Yilmaz D, Mazıcan N, Duman B, Ozguler Y, Musellim B, Hamuryudan V, Ongen G.

Respiration. 2015;90(3):191-8. doi: 10.1159/000434684. Epub 2015 Jun 30.

7.

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators.

N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. Erratum in: N Engl J Med. 2015 Aug 20;373(8):782.

8.

Evaluation of the Practice Pattern of Medical Patients' VTE Prophylaxis With a Standard Risk Assessment Model Form: MERAM Study.

Ongen G, Demir M, Molinas N, Ince B, Ongen Z.

Clin Appl Thromb Hemost. 2015 Jul;21(5):412-9. doi: 10.1177/1076029613505765. Epub 2013 Oct 10.

PMID:
24113493
9.

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P.

N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31. Erratum in: N Engl J Med. 2014 Jan 23;370(4):390.

10.

Riociguat for the treatment of pulmonary arterial hypertension.

Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ; PATENT-1 Study Group.

N Engl J Med. 2013 Jul 25;369(4):330-40. doi: 10.1056/NEJMoa1209655.

11.

A retrospective case-control study, factors affecting treatment outcomes for pulmonary tuberculosis in istanbul, Turkey.

Babalık A, Kılıçaslan Z, Kızıltaş S, Gencer S, Ongen G.

Balkan Med J. 2013 Jun;30(2):204-10. doi: 10.5152/balkanmedj.2013.005. Epub 2013 Jun 1.

12.

Monitoring of the effects of transfection with baculovirus on Sf9 cell line and expression of human dipeptidyl peptidase IV.

Ustün-Aytekin O, Gürhan ID, Ohura K, Imai T, Ongen G.

Cytotechnology. 2014 Jan;66(1):159-68. doi: 10.1007/s10616-013-9549-3. Epub 2013 May 29.

13.

Pulmonary tuberculosis incidence in Turkish prisons: importance of screening and case finding strategies.

Öngen G, Börekçi Ş, İçmeli ÖS, Birgen N, Karagül G, Akgün S, Kılıçaslan Z, Umut S.

Tuberk Toraks. 2013;61(1):21-7.

14.

Microbial transformation of cycloastragenol.

Kuban M, Öngen G, Khan IA, Bedir E.

Phytochemistry. 2013 Apr;88:99-104. doi: 10.1016/j.phytochem.2012.12.007. Epub 2013 Jan 26.

PMID:
23357596
15.

Production and separation of dipeptidyl peptidase IV from Lactococcus lactis: scale up for industrial production.

Ustün O, Ongen G.

Bioprocess Biosyst Eng. 2012 Oct;35(8):1417-27. doi: 10.1007/s00449-012-0730-4. Epub 2012 Jul 31.

PMID:
22847360
16.

The functional SLC11A1 gene polymorphisms are associated with sarcoidosis in Turkish population.

Akçakaya P, Azeroglu B, Even I, Ates O, Turker H, Ongen G, Topal-Sarikaya A.

Mol Biol Rep. 2012 Apr;39(4):5009-16. doi: 10.1007/s11033-011-1297-x. Epub 2011 Dec 8.

PMID:
22160516
17.

Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.

Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE; Cassiopea Investigators.

Lancet. 2012 Jan 14;379(9811):123-9. doi: 10.1016/S0140-6736(11)61505-5. Epub 2011 Nov 28.

PMID:
22130488
18.

Clinical presentations and diagnostic work-up in sarcoidosis: a series of Turkish cases (clinics and diagnosis of sarcoidosis).

Kıter G, Müsellim B, Cetinkaya E, Türker H, Kunt Uzaslan AE, Yentürk E, Uzun O, Sağlam L, Özdemir Kumbasar Ö, Celik G, Okumuş G, Arbak PM, Altıay G, Tabak L, Sakar Coşkun A, Erturan S, Türktaş H, Yalnız E, Akkoçlu A, Öğüş C, Doğan ÖT, Özkan M, Özkan S, Uzel FI, Öngen G; Sarcoidosis Working Group of Turkish Thoracic Society.

Tuberk Toraks. 2011;59(3):248-58.

19.

Survival in progressive systemic sclerosis with pulmonary involvement: a single-center experience in Istanbul, Turkey.

Zuhur F, Zuhur SS, Zuhur C, Musellim B, Ongen G.

Rheumatol Int. 2012 Jun;32(6):1655-61. doi: 10.1007/s00296-011-1842-x. Epub 2011 Mar 5.

PMID:
21373783
20.

The association between BsmI variant of vitamin D receptor gene and susceptibility to tuberculosis.

Ates O, Dolek B, Dalyan L, Musellim B, Ongen G, Topal-Sarikaya A.

Mol Biol Rep. 2011 Apr;38(4):2633-6. doi: 10.1007/s11033-010-0404-8. Epub 2010 Nov 20.

PMID:
21104028

Supplemental Content

Loading ...
Support Center